Annelie Liljegren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3201760/publications.pdf

Version: 2024-02-01

759055 839398 1,051 19 12 18 citations h-index g-index papers 19 19 19 3039 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
2	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
3	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
4	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
5	Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Research and Treatment, 2018, 167, 761-769.	1.1	45
6	Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Research and Treatment, 2012, 135, 791-798.	1.1	42
7	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
8	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
9	Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. British Journal of Cancer, 2016, 115, 1400-1407.	2.9	22
10	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
11	No difference in dose distribution in organs at risk in postmastectomy radiotherapy with or without breast implant reconstruction. Radiation Oncology, 2014, 9, 14.	1.2	15
12	Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast, 2009, 18, 259-262.	0.9	13
13	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
14	Post-mastectomy radiation therapy with or without implant-based reconstruction is safe in terms of clinical target volume coverage and survival $\hat{a} \in A$ matched cohort study. Radiotherapy and Oncology, 2019, 131, 229-236.	0.3	11
15	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
16	Physical therapy after prophylactic mastectomy with breast reconstruction: A prospective randomized study. Breast, 2014, 23, 357-363.	0.9	7
17	Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer. Breast Cancer Research and Treatment, 2018, 168, 655-666.	1.1	2
18	MSI Test to Distinguish between HNPCC and Other Predisposing Syndromes – of Value in Tailored Surveillance. Disease Markers, 2004, 20, 259-267.	0.6	1

Annelie Liljegren

#	Article	IF	CITATIONS
19	Safety of fertility preservation in women with breast cancer. Breast, 2019, 43, 149.	0.9	0